The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2016 | Monoclonal antibodies and checkpoint inhibitors for multiple myeloma
Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, USA provides an overview of monoclonal antibodies and checkpoint inhbitors for multiple myeloma at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Currently, two antibodies are approved for routine use in the USA: elotuzumab, which targets SLAMF7 and is combined with lenalidomide and dexamethasone, and daratumumab, which is currently approved as a single agent. Checkpoint inhibitors are another important class of drugs according to Prof Lonial. Several trials have been launched looking into nivolumab and pembrolizumab, which target PD-1, in combination with lenalidomide and pomalidomide. According to Prof Lonial, the question that will need to be answered is how to combine these drugs in order to increase the fraction of patients who can be cured.
